{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:04:39Z","timestamp":1793984679954,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA159981"],"award-info":[{"award-number":["P50CA159981"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32GM008803-11A1"],"award-info":[{"award-number":["T32GM008803-11A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA197780"],"award-info":[{"award-number":["R01CA197780"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["OC150553"],"award-info":[{"award-number":["OC150553"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Genomic instability (GI) predisposes cells to malignant transformation, however the molecular mechanisms that allow for the propagation of cells with a high degree of genomic instability remain unclear. Here we report that miR-181a is able to transform fallopian tube secretory epithelial cells through the inhibition of RB1 and stimulator-of-interferon-genes (STING) to propagate cells with a high degree of GI. MiR-181a targeting of RB1 leads to profound nuclear defects and GI generating aberrant cytoplasmic DNA, however simultaneous miR-181a mediated inhibition of STING allows cells to bypass interferon mediated cell death. We also found that high miR-181a is associated with decreased IFN\u03b3 response and lymphocyte infiltration in patient tumors. DNA oncoviruses are the only known inhibitors of STING that allow for cellular transformation, thus, our findings are the first to identify a miRNA that can downregulate STING expression to suppress activation of intrinsic interferon signaling. This study introduces miR-181a as a putative biomarker and identifies the miR-181a-STING axis as a promising target for therapeutic exploitation.<\/jats:p>","DOI":"10.1038\/s41467-020-17030-w","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T10:03:59Z","timestamp":1593165839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling"],"prefix":"10.1038","volume":"11","author":[{"given":"Matthew","family":"Knarr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita A.","family":"Avelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeja C.","family":"Sekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele L.","family":"Dziubinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-4690","authenticated-orcid":false,"given":"Jessica","family":"McAnulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Skala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Avril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-6977","authenticated-orcid":false,"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8319-6763","authenticated-orcid":false,"given":"Analisa","family":"DiFeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"17030_CR1","unstructured":"National Cancer Institute. Ovarian Cancer\u2014Cancer Stat Facts. (National Cancer Institute, 2019). https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html. Accessed 27 Jan 2019."},{"key":"17030_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","volume":"2","author":"MF Fathalla","year":"1971","unstructured":"Fathalla, M. F. Incessant ovulation\u2013a factor in ovarian neoplasia? Lancet 2, 163 (1971).","journal-title":"Lancet"},{"key":"17030_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020712-163949","volume":"9","author":"NN Nik","year":"2014","unstructured":"Nik, N. N., Vang, R., Shih, I.-M. & Kurman, R. J. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu. Rev. Pathol. 9, 27\u201345 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"17030_CR4","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","volume":"25","author":"MJ Callahan","year":"2007","unstructured":"Callahan, M. J. et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 25, 3985\u20133990 (2007).","journal-title":"J. Clin. Oncol."},{"key":"17030_CR5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","volume":"30","author":"F Medeiros","year":"2006","unstructured":"Medeiros, F. et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30, 230\u2013236 (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"17030_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.pgp.0000101082.35393.84","volume":"23","author":"ML Carcangiu","year":"2004","unstructured":"Carcangiu, M. L. et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int. J. Gynecol. Pathol. 23, 35\u201340 (2004).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"17030_CR7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger, D. W. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31, 161\u2013169 (2007).","journal-title":"Am. J. Surg. Pathol."},{"key":"17030_CR8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2008.01.012","volume":"109","author":"AK Folkins","year":"2009","unstructured":"Folkins, A. K. et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with heterozygous BRCA mutations. Gynecol. Oncol. 109, 168\u2013173 (2009).","journal-title":"Gynecol. Oncol."},{"key":"17030_CR9","doi-asserted-by":"crossref","first-page":"126295","DOI":"10.1155\/2010\/126295","volume":"2010","author":"AL Gross","year":"2010","unstructured":"Gross, A. L., Kurman, R. J., Vang, R., Shih, I.-M. & Visvanathan, K. Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J. Oncol. 2010, 126295 (2010).","journal-title":"J. Oncol."},{"key":"17030_CR10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JMJ Piek","year":"2001","unstructured":"Piek, J. M. J. et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195, 451\u2013456 (2001).","journal-title":"J. Pathol."},{"key":"17030_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/path.4230","volume":"231","author":"A Bashashati","year":"2013","unstructured":"Bashashati, A. et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 231, 21\u201334 (2013).","journal-title":"J. Pathol."},{"key":"17030_CR12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","volume":"211","author":"Y Lee","year":"2007","unstructured":"Lee, Y. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211, 26\u201335 (2007).","journal-title":"J. Pathol."},{"key":"17030_CR13","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy, S. I. et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 8, 1093 (2017).","journal-title":"Nat. Commun."},{"key":"17030_CR14","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","volume":"6","author":"MA Eckert","year":"2016","unstructured":"Eckert, M. A. et al. Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube. Cancer Discov. 6, 1342\u20131351 (2016).","journal-title":"Cancer Discov."},{"key":"17030_CR15","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3977","volume":"5","author":"A Parikh","year":"2014","unstructured":"Parikh, A. et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial\u2013mesenchymal transition. Nat. Commun. 5, ncomms3977 (2014).","journal-title":"Nat. Commun."},{"key":"17030_CR16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.stemcr.2018.12.002","volume":"12","author":"A Belur Nagaraj","year":"2019","unstructured":"Belur Nagaraj, A. et al. A miRNA-mediated approach to dissect the complexity of tumor-initiating cell function and identify miRNA-targeting drugs. Stem Cell Rep. 12, 122\u2013134 (2019).","journal-title":"Stem Cell Rep."},{"key":"17030_CR17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","volume":"74","author":"AM Karst","year":"2014","unstructured":"Karst, A. M. et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 74, 1141\u20131152 (2014).","journal-title":"Cancer Res."},{"key":"17030_CR18","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/onc.2015.288","volume":"35","author":"G Hua","year":"2016","unstructured":"Hua, G. et al. YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. Oncogene 35, 2247\u20132265 (2016).","journal-title":"Oncogene"},{"key":"17030_CR19","doi-asserted-by":"crossref","first-page":"a000661","DOI":"10.1101\/cshperspect.a000661","volume":"2","author":"V Lallemand-Breitenbach","year":"2010","unstructured":"Lallemand-Breitenbach, V. & de Th\u00e9, H. PML nuclear bodies. Cold Spring Harb. Perspect. Biol. 2, a000661 (2010).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"17030_CR20","doi-asserted-by":"crossref","first-page":"a026096","DOI":"10.1101\/cshperspect.a026096","volume":"6","author":"CM Eischen","year":"2016","unstructured":"Eischen, C. M. Genome stability requires p53. Cold Spring Harb. Perspect. Med. 6, a026096 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"17030_CR21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding, S. M. et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548, 466\u2013470 (2017).","journal-title":"Nature"},{"key":"17030_CR22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie, K. J. et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548, 461\u2013465 (2017).","journal-title":"Nature"},{"key":"17030_CR23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830.e14 (2018).","journal-title":"Immunity"},{"key":"17030_CR24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4927","volume":"243","author":"Y Zhai","year":"2017","unstructured":"Zhai, Y. et al. High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease. J. Pathol. 243, 16\u201325 (2017).","journal-title":"J. Pathol."},{"key":"17030_CR25","first-page":"65","volume":"60","author":"PS Rabinovitch","year":"1989","unstructured":"Rabinovitch, P. S., Reid, B. J., Haggitt, R. C., Norwood, T. H. & Rubin, C. E. Progression to cancer in Barrett\u2019s esophagus is associated with genomic instability. Lab. Investig. 60, 65\u201371 (1989).","journal-title":"Lab. Investig."},{"key":"17030_CR26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2159-8290.CD-15-0412","volume":"5","author":"N Murugaesu","year":"2015","unstructured":"Murugaesu, N. et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 5, 821\u2013831 (2015).","journal-title":"Cancer Discov."},{"key":"17030_CR27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3748\/wjg.v21.i2.616","volume":"21","author":"BM Shivakumar","year":"2015","unstructured":"Shivakumar, B. M. et al. Copy number variations are progressively associated with the pathogenesis of colorectal cancer in ulcerative colitis. World J. Gastroenterol. 21, 616\u2013622 (2015).","journal-title":"World J. Gastroenterol."},{"key":"17030_CR28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature13600","volume":"512","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155\u2013160 (2014).","journal-title":"Nature"},{"key":"17030_CR29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"17030_CR30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/path.4000","volume":"228","author":"Z Liu","year":"2012","unstructured":"Liu, Z. et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J. Pathol. 228, 204\u2013215 (2012).","journal-title":"J. Pathol."},{"key":"17030_CR31","doi-asserted-by":"crossref","first-page":"38983","DOI":"10.18632\/oncotarget.5493","volume":"6","author":"Y Liu","year":"2015","unstructured":"Liu, Y. et al. Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. Oncotarget 6, 38983\u201338998 (2015).","journal-title":"Oncotarget"},{"key":"17030_CR32","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.1017300108","volume":"108","author":"AM Karst","year":"2011","unstructured":"Karst, A. M., Levanon, K. & Drapkin, R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl Acad. Sci. USA 108, 7547\u20137552 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"17030_CR33","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.4161\/cc.20544","volume":"11","author":"W Shan","year":"2012","unstructured":"Shan, W. et al. Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle 11, 2107\u20132113 (2012).","journal-title":"Cell Cycle"},{"key":"17030_CR34","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1158\/0008-5472.CAN-05-1543","volume":"65","author":"SD Kendall","year":"2005","unstructured":"Kendall, S. D., Linardic, C. M., Adam, S. J. & Counter, C. M. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res. 65, 9824\u20139828 (2005).","journal-title":"Cancer Res."},{"key":"17030_CR35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1593\/neo.11138","volume":"13","author":"AA Jazaeri","year":"2011","unstructured":"Jazaeri, A. A. et al. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 13, 899\u2013911 (2011).","journal-title":"Neoplasia"},{"key":"17030_CR36","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1101\/gad.282145.116","volume":"30","author":"NJ Dyson","year":"2016","unstructured":"Dyson, N. J. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 30, 1492\u20131502 (2016).","journal-title":"Genes Dev."},{"key":"17030_CR37","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nature02820","volume":"430","author":"E Hernando","year":"2004","unstructured":"Hernando, E. et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430, 797\u2013802 (2004).","journal-title":"Nature"},{"key":"17030_CR38","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1101\/gad.288282.116","volume":"30","author":"R V\u00e9lez-Cruz","year":"2016","unstructured":"V\u00e9lez-Cruz, R. et al. RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1. Genes Dev. 30, 2500\u20132512 (2016).","journal-title":"Genes Dev."},{"key":"17030_CR39","doi-asserted-by":"crossref","first-page":"23867","DOI":"10.1074\/jbc.M700542200","volume":"282","author":"SV Srinivasan","year":"2007","unstructured":"Srinivasan, S. V., Mayhew, C. N., Schwemberger, S., Zagorski, W. & Knudsen, E. S. RB loss promotes aberrant ploidy by deregulating levels and activity of DNA replication factors. J. Biol. Chem. 282, 23867\u201323877 (2007).","journal-title":"J. Biol. Chem."},{"key":"17030_CR40","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1101\/gad.1917310","volume":"24","author":"AL Manning","year":"2010","unstructured":"Manning, A. L., Longworth, M. S. & Dyson, N. J. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev. 24, 1364\u20131376 (2010).","journal-title":"Genes Dev."},{"key":"17030_CR41","doi-asserted-by":"crossref","first-page":"e18065","DOI":"10.1371\/journal.pone.0018065","volume":"6","author":"CH Pratt","year":"2011","unstructured":"Pratt, C. H., Curtain, M., Donahue, L. R. & Shopland, L. S. Mitotic defects lead to pervasive aneuploidy and accompany loss of RB1 activity in mouse LmnaDhe dermal fibroblasts. PLoS ONE 6, e18065 (2011).","journal-title":"PLoS ONE"},{"key":"17030_CR42","doi-asserted-by":"crossref","first-page":"17873","DOI":"10.18632\/oncotarget.4286","volume":"6","author":"P Indovina","year":"2015","unstructured":"Indovina, P. et al. RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget 6, 17873\u201317890 (2015).","journal-title":"Oncotarget"},{"key":"17030_CR43","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.onc.1209103","volume":"25","author":"MT Pickering","year":"2006","unstructured":"Pickering, M. T. & Kowalik, T. F. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene 25, 746\u2013755 (2006).","journal-title":"Oncogene"},{"key":"17030_CR44","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2121-10-79","volume":"10","author":"A Amato","year":"2009","unstructured":"Amato, A., Lentini, L., Schillaci, T., Iovino, F. & Di Leonardo, A. RNAi mediated acute depletion of retinoblastoma protein (pRb) promotes aneuploidy in human primary cells via micronuclei formation. BMC Cell Biol. 10, 79 (2009).","journal-title":"BMC Cell Biol."},{"key":"17030_CR45","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3390\/ijms18081776","volume":"18","author":"R V\u00e9lez-Cruz","year":"2017","unstructured":"V\u00e9lez-Cruz, R. & Johnson, D. The retinoblastoma (RB) tumor suppressor: pushing back against genome instability on multiple fronts. Int. J. Mol. Sci. 18, 1776 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"17030_CR46","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1541-7786.MCR-17-0084","volume":"15","author":"Z Yang","year":"2017","unstructured":"Yang, Z., Maciejowski, J. & De Lange, T. Oncogenes and tumor suppressors nuclear envelope rupture is enhanced by loss of p53 or Rb. Mol Cancer Res. 15,\u00a01579\u20131586 (2017).","journal-title":"Mol Cancer Res."},{"key":"17030_CR47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: implications for cancer therapy. Nat. Rev. Cancer 16, 131\u2013144 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"17030_CR48","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.it.2015.09.007","volume":"36","author":"AJ Minn","year":"2015","unstructured":"Minn, A. J. Interferons and the immunogenic effects of cancer therapy. Trends Immunol. 36, 725\u2013737 (2015).","journal-title":"Trends Immunol."},{"key":"17030_CR49","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li, T. & Chen, Z. J. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J. Exp. Med. 215, 1287\u20131299 (2018).","journal-title":"J. Exp. Med."},{"key":"17030_CR50","first-page":"3092","volume":"20","author":"G Liu","year":"2016","unstructured":"Liu, G., Li, Y. & X.-G., G. microRNA-181a is upregulated in human atherosclerosis plaques and involves in the oxidative stress-induced endothelial cell dysfunction through direct targeting Bcl-2. Eur. Rev. Med. Pharmacol. Sci. 20, 3092\u20133100 (2016).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"17030_CR51","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbrc.2012.11.097","volume":"430","author":"W Xie","year":"2013","unstructured":"Xie, W., Li, Z., Li, M., Xu, N. & Zhang, Y. miR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivo. Biochem. Biophys. Res. Commun. 430, 647\u2013652 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"17030_CR52","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1194\/jlr.M028878","volume":"53","author":"C Wu","year":"2012","unstructured":"Wu, C. et al. microRNA-181a represses ox-LDL-stimulated inflammatory response in dendritic cell by targeting c-Fos. J. Lipid Res. 53, 2355\u20132363 (2012).","journal-title":"J. Lipid Res."},{"key":"17030_CR53","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1078-0432.CCR-17-1621","volume":"24","author":"DW Garsed","year":"2018","unstructured":"Garsed, D. W. et al. Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer. Clin. Cancer Res. 24, 569\u2013580 (2018).","journal-title":"Clin. Cancer Res."},{"key":"17030_CR54","doi-asserted-by":"crossref","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","volume":"109","author":"EE Parkes","year":"2017","unstructured":"Parkes, E. E. et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J. Natl Cancer Inst. 109, djw199 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"17030_CR55","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1078-0432.CCR-17-3022","volume":"24","author":"G Peng","year":"2018","unstructured":"Peng, G. & Mills, G. B. Surviving ovarian cancer: an affair between defective DNA repair and RB1. Clin. Cancer Res. 24, 508\u2013510 (2018).","journal-title":"Clin. Cancer Res."},{"key":"17030_CR56","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/nprot.2012.097","volume":"7","author":"AM Karst","year":"2012","unstructured":"Karst, A. M. & Drapkin, R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat. Protoc. 7, 1755\u20131764 (2012).","journal-title":"Nat. Protoc."},{"key":"17030_CR57","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3977","volume":"5","author":"A Parikh","year":"2014","unstructured":"Parikh, A. et al. MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat. Commun. 5, 2977 (2014).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17030-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T23:41:41Z","timestamp":1670283701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17030-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["17030"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-17030-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"20 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3231"}}